Here below are the publications (6) participated by Andrea Alimonti using the term string tumor (as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations).
Any wrong or incomplete data? Any missing, misplaced, unlicensed picture? Please report any abuse, inaccuracy or lack of information to info@ticinoscienza.ch

1) Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells
Cancer Cell, 8 aprile 2024

2) VSSP-activated macrophages mediate senescence and tumor inhibition in a preclinical model of advanced prostate cancer
Cell Communication and Signaling, 13 aprile 2023

3) Enhancing chemotherapy efficacy by reprogramming the senescence-associated secretory phenotype of prostate tumors: A way to reactivate the antitumor immunity
OncoImmunology, 22 gennaio 2015

4) Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer
Cell Reports, 28 aprile 2015

5) Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity
Cell Reports, 9 ottobre 2014

6) CDCP1 expression is frequently increased in aggressive urothelial carcinoma and promotes urothelial tumor progression
Scientific Reports, 2 gennaio 2023
Andrea Alimonti
is currently collaborating with
Istituto Oncologico di Ricerca (IOR) (Rif. IOR)
Via Francesco Chiesa 5
6500 Bellinzona
Andrea Alimonti
on behalf of
Istituto Oncologico di Ricerca (IOR) USI (Rif. IOR)
is currently participating in the Research Group
Molecular Oncology
as Group Leader [Rif. 55110]